Journal article · 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
New England Journal of Medicine, 394(4), 354–366 · Published 21 January 2026 · DOI 10.1056/nejmoa2508959
In brief
“Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer” is a 2026 journal article by Sara M. Tolaney and 19 co-authors, published in New England Journal of Medicine. OpenAlex counts 130 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 130
- Most cited in
- 2026 (129)
- Field-weighted impact
- 219.97
- References
- 17
- Authors
- 20
Abstract
BACKGROUND: Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer. METHODS: In this phase 3, open-label, international trial, we randomly assigned patients in a 1:1 ratio to receive… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Tolaney, S. M., de Azambuja, E., Kalinsky, K. M., Loi, S., Kim, S., Yam, C., Rapoport, B. L., Im, S., Pistilli, B., McHayleh, W. M., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas‐Júnior, R., Bofill, J. S., Afshari, M., Gary, D., Wang, L., Lai, C., & Schmid, P. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354–366. https://doi.org/10.1056/nejmoa2508959
MLA 9
Tolaney, Sara M., et al. “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.” New England Journal of Medicine, vol. 394, no. 4, 2026, pp. 354–366. https://doi.org/10.1056/nejmoa2508959.
Chicago
Tolaney, Sara M., Evandro de Azambuja, Kevin M. Kalinsky, Sherene Loi, Sung‐Bae Kim, Clinton Yam, Bernardo Leon Rapoport, et al. 2026. “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.” New England Journal of Medicine 394 (4): 354–366. https://doi.org/10.1056/nejmoa2508959.
Harvard
Tolaney, S. M. et al. (2026) ‘Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer’, New England Journal of Medicine, 394(4), pp. 354–366. doi:10.1056/nejmoa2508959.
IEEE
S. M. Tolaney et al., “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer,” New England Journal of Medicine, vol. 394, no. 4, pp. 354–366, 2026, doi: 10.1056/nejmoa2508959.
BibTeX
@article{tolaney2026sacituzumab,
title = {{Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer}},
author = {Tolaney, Sara M. and de Azambuja, Evandro and Kalinsky, Kevin M. and Loi, Sherene and Kim, Sung‐Bae and Yam, Clinton and Rapoport, Bernardo Leon and Im, Seock‐Ah and Pistilli, Barbara and McHayleh, Wassim M. and Cescon, David W. and Watanabe, Junichiro and Bañuelas, Manuel Alejandro Lara and Freitas‐Júnior, Ruffo and Bofill, Javier Salvador and Afshari, Maryam and Gary, Dianna and Wang, Lu and Lai, Catherine and Schmid, Peter},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {4},
pages = {354--366},
doi = {10.1056/nejmoa2508959},
url = {https://doi.org/10.1056/nejmoa2508959}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- sacituzumab govitecan
- pembrolizumab
- triple-negative breast cancer
- PD-L1-positive
- metastatic breast cancer
- combination immunotherapy
- progression-free survival
- objective response
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Tolaney, S. M., de Azambuja, E., Kalinsky, K. M., Loi, S., Kim, S., Yam, C., Rapoport, B. L., Im, S., Pistilli, B., McHayleh, W. M., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas‐Júnior, R., Bofill, J. S., Afshari, M., Gary, D., Wang, L., Lai, C., & Schmid, P. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354–366. https://doi.org/10.1056/nejmoa2508959
How many times has this paper been cited?
130 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Sara M. Tolaney, Evandro de Azambuja, Kevin M. Kalinsky, Sherene Loi, Sung‐Bae Kim, Clinton Yam, Bernardo Leon Rapoport, Seock‐Ah Im, Barbara Pistilli, Wassim M. McHayleh, David W. Cescon, Junichiro Watanabe and 8 more.
What is the DOI of this paper?
10.1056/nejmoa2508959, permanently at https://doi.org/10.1056/nejmoa2508959. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.